Gain Therapeutics (NASDAQ:GANX) Issues Quarterly Earnings Results

Gain Therapeutics (NASDAQ:GANX) issued its earnings results on Tuesday. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03, Zacks reports.

Gain Therapeutics Price Performance

Gain Therapeutics stock traded up $0.15 during trading hours on Tuesday, hitting $1.92. The stock had a trading volume of 159,283 shares, compared to its average volume of 794,695. Gain Therapeutics has a 1-year low of $1.46 and a 1-year high of $4.34. The stock has a market capitalization of $81.76 million, a price-to-earnings ratio of -3.31 and a beta of 0.19. The stock’s fifty day moving average is $1.78 and its two-hundred day moving average is $1.93. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.69 and a quick ratio of 4.69.

Institutional Investors Weigh In On Gain Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in GANX. Marshall Wace LLP grew its stake in Gain Therapeutics by 849.3% in the 4th quarter. Marshall Wace LLP now owns 1,662,293 shares of the company’s stock valued at $5,353,000 after acquiring an additional 1,487,186 shares during the last quarter. Jane Street Group LLC raised its position in Gain Therapeutics by 234.5% during the fourth quarter. Jane Street Group LLC now owns 242,328 shares of the company’s stock worth $780,000 after acquiring an additional 169,878 shares during the last quarter. LPL Financial LLC acquired a new position in Gain Therapeutics during the fourth quarter worth about $343,000. State Street Corp lifted its holdings in shares of Gain Therapeutics by 72.9% in the fourth quarter. State Street Corp now owns 157,537 shares of the company’s stock valued at $507,000 after purchasing an additional 66,400 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Gain Therapeutics by 15.6% in the fourth quarter. Geode Capital Management LLC now owns 397,942 shares of the company’s stock valued at $1,282,000 after purchasing an additional 53,796 shares in the last quarter. 11.97% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GANX has been the topic of a number of analyst reports. Oppenheimer restated an “outperform” rating on shares of Gain Therapeutics in a research note on Wednesday, May 27th. Weiss Ratings cut Gain Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 9th. Wall Street Zen raised Gain Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, June 21st. Roth Capital restated a “buy” rating on shares of Gain Therapeutics in a research report on Tuesday, May 12th. Finally, BTIG Research reaffirmed a “buy” rating and set a $5.00 price target on shares of Gain Therapeutics in a research note on Tuesday, June 30th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Gain Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $7.50.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.